Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery moves US base to Kendall Square

Sygnature Discovery’s US office has moved, our new location is 245 First Street in Cambridge, MA, near Kendall Square, the heart of the Cambridge–Boston biotech hub, just a couple of miles down the road from our old location near Harvard Square. 

‘We have seen the benefits of having a physical presence in Harvard Square, and it has served us really well,’ said Anders Lindstrom, Director of Marketing at Sygnature. ‘The opportunity to move closer to the Kendall Square centre of the biotech cluster was one we could not pass up. One of our key strengths is our collaborative approach to drug discovery, and a physical presence as close as possible to customers is important, so this crucible of drug discovery is the perfect place for us.’ Lindstrom added.

The US has been a significant market for Sygnature ever since we entered the drug discovery sector 15 years ago, and the first customer was US-based. Many Sygnature scientists studied and worked at US institutions, including MIT and Harvard. Half of the company’s business is now in the US, with customers all across the country from West Coast to East Coast and between.

The company is experiencing huge demand from US companies, ranging from big pharma to small university spinouts. Sygnature’s SVP of Business Development, Paul Clewlow commented: ‘We believe the services and expertise we have within Sygnature is perfectly tuned to providing the resource and expertise our customers need to take forward their innovative drug discovery programmes. A huge amount of exciting drug discovery is going on in the Boston–Cambridge area – not just biotechs, but big pharma is congregating there now as well. It is a great hub for us from where to better serve our North American customer base’. 

So, if you are based in the area or happen to be visiting, please feel free to pop in for a visit. And you can of course always visit our website for a browse, or get in touch via email


Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…